Publications by authors named "Nighat Anjum"

2 Publications

  • Page 1 of 1

Effects of co-administration of pharmacopoeia formulations and with CAT-I antitubercular drugs in rats.

J Complement Integr Med 2021 May 10. Epub 2021 May 10.

ICMR-National Institute for Research in Tuberculosis (NIRT), Chennai, Tamil Nadu, India.

Objectives: Tuberculosis continues to be a major public health problem globally, despite incredible advancements in healthcare system. In system of medicine, (QTS) and (AHB) have been traditionally used for tuberculosis like conditions. The study was aimed to investigate the effects of co-administration of QTS and AHB with category I first line antitubercular drugs (CAT-I) on the indices of liver and kidney function in rats.

Methods: QTS and AHB were prepared individually and mixed to achieve final compound pharmacopoeia formulation (UPF). The human equivalent doses for rats were calculated and administered with and without CAT-I. The effects of the formulations on serum indices of kidney and liver function, hematological markers and plasma CAT-I drug levels were estimated at 14th, 60th & 180th days of treatment.

Results: The administration of UPF, CAT-I and UPF + CAT-I altered the levels of aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) and gamma glutamyltransferase (GGT) and haematological markers. These alterations were within permissible range and randomly distributed among groups during various time points. Administration of CAT-I alone resulted in moderate histopathological changes which were completely abrogated in CAT-I + UPF co-administered animals. The co-administration of UPF with CAT-I improved the plasma peak rifampicin (RIF) levels, without altering the liver and kidney functions.

Conclusions: The co-administration of UPF with ATT improved liver and kidney functions and increased the plasma levels of RIF. These beneficial findings provide a scope to evaluate the pharmacokinetic studies in humans.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
May 2021

Lithotriptic effect of in patients of (Nephrolithiasis) - an open prospective clinical validation trial.

J Complement Integr Med 2020 May 19;18(1):139-146. Epub 2020 May 19.

Central Council for Research in Unani Medicine, New Delhi, Ministry of AYUSH, Govt of India, India.

Background: (Nephrolithiasis) is one of the most common chronic conditions and has been known to the mankind since antiquity. The incidence is increasing globally with geographic, racial and gender variation in its occurrence. Medical management of Nephrolithiasis still poses a considerable challenge for modern medical practice. Unani drugs possessing lithotriptic activity are not only cost effective but also have least side effects. has been used since long for the treatment of (Nephrolithiasis) but no documentary evidence based on scientific parameters as to its safety and efficacy are available.

Objective: To validate the safety and efficacy of in the treatment of .

Methodology: An open prospective clinical trial was carried out on 107 subjects of renal calculi of 3-7 mm diameter diagnosed by Ultrasonogram-KUB (USG-KUB). Subjects were evaluated by clinical history & examination, laboratory investigations followed by USG-KUB for confirmation. The safety was assessed by reporting of adverse events and by pathological and biochemical investigations. Assessment of efficacy was based on improvement observed in VAS score and expulsion/reduction of stone size as detected by USG-KUB.

Results: Substantial reduction (53%) in the size of calculi confirmed by USG-KUB and considerable lowering of VAS score (75%) were observed with the active intervention in majority of the cases.

Conclusion: The trial has revealed that the Unani pharmacopoeal formulation was well tolerated and has the therapeutic potential in the reduction and expulsion of renal calculi.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
May 2020